Pharvaris
ExitedPharvaris is a clinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients.
Pharvaris has raised €67M across 1 funding round from 2 investors, most recently a Series C round in Nov 2020. Based in Zug, Switzerland; founded 2015; active in Healthtech. The company has exited (2025). Data as of 28 Oct 2026.
Total raised
€67M
€67,328,733
Funding rounds
1
Investors
2
distinct backers
Active since
2020-11
latest 2020-11
Funding by year
EUR raised per yearPharvaris — funding by year — interactive chart.
Data table
| Pharvaris — funding by year | |
|---|---|
| 2020 | €67M |
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-11-18 | Series C | €67M | General Atlantic,Viking Global Investors | View deal → |
Exit
Type
ipo
Date
Jul 2025
Value
€172M
Acquiror
—
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData